TY -的T1 -认知概要Amyloid-Positive轻度认知障碍和阿尔茨海默病,没有τ(p2.1 - 030) JF -神经学乔-神经学六世- 92 - 15补充SP - p2.1 - 030 AU -劳伦McCollum AU -劳拉与非盟- Sandhitsu Das A首页U -罗宾·德·弗洛雷斯AU -保罗Yushkevich AU -大卫Wolk Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p2.1 - 030. -文摘N2 -目的:确定不同的认知Amyloid-Positive个人资料(+)和轻度认知障碍(MCI)和阿尔茨海默病(AD)和未伴有病理性τ(T + / T−)。背景:异质性在广告和病理学的主要来源(如与AD病理血管),构成挑战的研究和临床护理。最近开发了ATN框架广告病理学分类个人基于淀粉样蛋白(A),τ(T)和神经退行性变的(N)的地位。τ病理学是直接与神经细胞退化和广告的认知能力下降有关。因此,认知障碍在设定的淀粉样蛋白没有τ显示另一个司机神经损伤。设计/方法:数据来自ADNI利用。入选标准是淀粉样积极性(基于复合SUVR 1.11 florbetapir PET)和MCI诊断或广告。τ截止1.22 SUVR双边extrahippocampal内侧颞叶使用小说τPET示踪av - 1451来自amyloid-negative控制。A + T−和A + T +组比较。结果:43 amyloid-positive MCI患者或广告满足入选标准:13 + T−和30 A + T +。A + T−组年龄(75.8 vs 69.9年,p = 0.026),有更高的MMSE (27.2 vs 24.2, p = 0.044),和更好的口头记忆得分(AVTOT6 5.31 vs 2.70, p = 0.024)。然而,A + T−组表现糟糕,小径B,衡量执行功能/测序,但这并没有达到意义(145.5 vs 131.1, p = 0.628)。Conclusions: Amongst a cohort of amyloid-positive MCI and AD, tau-negative individuals displayed clinical differences from counterparts with concomitant tau pathology, including somewhat better memory, but, if anything, relatively more affected executive function. The less AD-like pattern of the A+T− group may support the notion that symptomatic patients who are A+T− may have non-AD pathologies driving their clinical symptoms. Further investigation will examine the burden of white matter hyperintensities, a marker of vascular disease, and patterns of cortical thickness in these groups.Disclosure: Dr. McCollum has nothing to disclose. Dr. Wisse has nothing to disclose. Dr. Das has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Rancho Biosciences. Dr. de Flores has nothing to disclose. Dr. Yushkevich has nothing to disclose. Dr. Wolk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Jannsen, Eli Lilly and GE. ER -